LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma” or the "Company ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Canaccord Genuity maintained a Buy rating on Verona Pharma (NASDAQ:VRNA) while significantly increasing the price target to $72.00 from the previous $44.00. According to InvestingPro data, analyst ...

Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...

Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated ...

David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said: "We are very pleased that Ohtuvayre TM is available to help patients still experiencing daily COPD symptoms.

SHANGHAI, Feb. 7, 2025 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance ...

SHANGHAI, Feb. 7, 2025 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of ...